TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE D-

NCT07573462: A PHASE 3, RANDOMIZED, DOUBLE-BLINDED TRIAL TO EVALUATE THE SAFETY AND TOLERABILITY OF A MULTIVALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS

Sponsor: Pfizer · Phase: PHASE3 · Area: INFECTIOUS_VACCINE · Target Enrollment: 2400 pts

Competing Trials Overlap

11 Active Trials

Excess Burn Exposure

$8,725,332

Rescue Site Savings

+$5,761,224

Unlock Full NCT07573462 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07573462 Rescue Dossier →